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Abstract 
Introduction: Centruroides F(ab’)2 antivenom (AV) is a safe and effective treatment for bark 
scorpion envenomation; however, concern exists regarding the substantial charges associated 
with this therapy and resulting unexpected costs of treatment.  This retrospective review seeks 
to quantitate patient charges associated with antivenom use to better understand its impact on 
patient and healthcare economics. 
Methods: This is a retrospective review of 527 patients presenting to a hospital system with 
severe scorpion envenomation between April 2013 and May 2015. Included patients had 
Centruroides scorpion envenomation and received AV. They were excluded if they were not a 
grade III or IV envenomation, did not receive antivenom or their clinical records were not 
available. Patient charges and hospital costs were acquired from institutional financial records 
and were included if total costs were accurate as defined by costs > $2500.  Clinical 
manifestations, length of stay (LOS), method and amount of AV administration were abstracted. 
Continuous data were reported as medians with interquartile range and linear regression was 
utilized to determine predictors of outcomes.    
Results: All patients had a grade 3 or 4 envenomation and received AV. The total number of 
vials received were 1 (18.2)% to a maximum of 7 (0.4%) with most patients receiving three vials 
(46.7%).  Most patients received three vials of antivenom initially (52.6%) as compared to one 
vial (43.6%) and only few receiving two vials (3.8%). Median total charges were $28,060 
($18,805 - $33,742). Linear regression showed that total charges were predicted by total 
number of vials administered and LOS (adjusted R2 of 0.75). Charges of care were found to 
increase by $7901.59 per vial of AV and by $415.48 for each hour of LOS. The only predictors of 
total charges were age, number of vials and total length of stay.  Correlation between total 
charges and costs was poor. 
Conclusions: Despite established safety and efficacy, anticipated patient charges appear to 
influence the manner in which bark scorpion antivenom is administered by healthcare 
providers.
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INTRODUCTION 
There are on average, sixteen thousand scorpion envenomations reported to US poison control 
center annually with approximately 1400 (8%) referred to healthcare facility for treatment. 
(Mowry 2013 - 15) Of those that had an envenomation recorded with the poison control center, 
death occurred in 0.002% of cases from 2013 to 2015. Historically, severe scorpion 
envenomation in Arizona was treated with a whole IgG antivenom (AV) made from goat serum 
this was available only in Arizona and its use was on a compassionate basis. The manufacturing 
of this antivenom was discontinued and stocks were exhausted in 2004. When this AV became 
unavailable care of severe scorpion envenomation was largely supportive which in pediatric 
patients often necessitated admission to ICU for titration of benzodiazepines and opioids and at 
times intubation and mechanical ventilation. It was during this period one study noted a 500% 
increase in admissions for scorpion envenomation. (Lovecchio, Pizon) In 2011 an FDA approved 
AV became available in the United States. This product has been used in Mexico for many years 
and its effectiveness is well established. The current FDA-approved dosing stipulates an initial 
dose of 3 vials followed by additional 1 vial doses every 30-60 minutes as clinical signs 
necessitate. The rare but main adverse reaction of concern being hypersensitivity reactions.  
In international markets this product is available at a cost of approximately fifty dollars per vial. 
(Volentine 2017)( In the US there have been several reports in the lay press highlighting the 
unexpectedly high patient charge associated with treatment with Centruroides F(ab’)2 
antivenom (AV). Healthcare providers in regions with a high prevalence of Centruroides 
envenomations are well aware of its cost, and some utilize alternative dosing regimens in an 
effort to are mitigate costs and preserve resources. (Bush 2015) 
The primary objective of this retrospective review was to quantitate the financial impact of 
treatment with this AV by presenting charges billed to the patient in comparison to costs of 
treatment with AV. Secondary outcomes included total dose of AV, its method of 
administration, specifically initial dose. In addition, clinical manifestations, grade of 
envenomation, complications and adjunctive treatments utilized were evaluated.  
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METHODS 
This study was an IRB approved retrospective review of patients presenting to a hospital system 
(data obtained from 11 healthcare facilities) with severe scorpion envenomation from April 
2013 to May 2015. These cases were identified via search of pharmacy and financial records for 
patients that received Centruroides F(ab’)2 antivenom. The electronic health record for all 
subjects receiving AV for which total charges and costs were available were reviewed and data 
abstracted. Inclusion criteria were those with clinical signs of severe scorpion envenomation 
that received antivenom. Exclusion criteria included patients not receiving antivenom or if 
clinical records were unavailable. 
Study Subjects 
Pharmacy and financial records were queried to identify patients receiving AV and their total 
charges vs direct costs between April 2013 and May 2015. Any patients without a clinical 
findings consistent with severe scorpion envenomation or who did not receive antivenom were 
excluded from further review.  
Outcome Measures 
The primary objective of this study is to describe patient charges and hospital costs related to 
care of severe scorpion envenomation using Centruroides F(ab’)2 antivenom (AV), including 
variables that predicted total charges.  Secondary outcomes included, amount of AV utilized, 
method of administration of AV (initial dose), clinical manifestations, complications, length of 
stay in patients who present for care following severe bark scorpion envenomation.   
Data Collection & Definitions 
Financial records were obtained from query of institutional software, TSI, and included billed 
charges, hospital cost, and fraction reimbursed associated with the visit. Clinical data was 
abstracted from the electronic medical record (Cerner) onto a pre-designed data abstraction 
sheet by four of the authors after undergoing an instructional session to ensure consistency. 
Data abstracted was subsequently entered into a spreadsheet (Excel 2000, version 9.0.2770; 
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Microsoft Redmond WA) by two members of the study staff.  In addition to total charges and 
direct costs, antivenom administration with total number of vials received by each patient and 
the method of delivery and adverse reactions to AV were abstracted in addition to clinical 
details. The clinical information collected included: age, gender, time and date of scorpion sting, 
onset of symptoms, patient complaints, any treatments prior to arrival, all medications given, IV 
fluids, oxygen administration, procedures. Additionally, clinical signs of envenomation and 
physical exam findings were collected, including vital signs, maximal temperature, oxygen 
saturation, pain, cranial nerve and neuromuscular involvement, peak creatine phosphokinase 
(CPK) and creatinine, EKG, whether a chest x-ray was performed and if evidence of aspiration 
was present were all recorded.  Finally, length of stay in hours and patient outcomes including 
complications or relevant clinical data were recorded.   
The following definitions were used: rhabdomyolysis defined as CPK ≥ 1000 IU/L; hypoxia O2 
saturation <90%, fever temperature > 38o C; hypertension (HTN) adult SBP> 140 or DBP> 90 
mmHg, tachycardia adults heart rate > 100 beats per minute, tachypnea adults respiratory rate 
> 20 breaths per minute. Hypertension, tachycardia and tachypnea for pediatric patients were 
based on vital sign measurements exceeding age-based norms as published in Pedi STAT. 
Grade of envenomation was based on the previously published criteria as outlined in the table 
below. Grade assigned by clinician providing care was abstracted and compared to grade 
assigned by member of the study staff performing the chart review. Severe envenomation is 
defined as Grade III or higher. 
Statistics 
Categorical variables were reported as valid percent to account for missing data. Continuous 
data were reported as median with interquartile range, and linear regression was utilized to 
determine predictors of outcomes. Logistic regression was used to determine predictors of in-
patient admission.  
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Figure 1. Clinical Grading & Definitions of Scorpion Envenomation 
Grade Clinical Manifestation 
I Local pain and/or paraesthesias 
II Grade I, plus pain and/or paraesthesias remote from the site of the sting 
III Either  
Cranial nerve dysfunction (blurred vision, wandering eye movements, 
hypersalivation, trouble swallowing, tongue fasciculation, problems with 
upper airway, slurred speech) 
or skeletal neuromuscular dysfunction (jerking of extremities, restlessness, 
severe involuntary motor activity) 
IV Both cranial nerve and skeletal neuromuscular dysfunction 
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RESULTS 
527 patients with severe scorpion envenomation that received antivenom therapy were 
included. Median (IQR) age was 4 (1.83-9) years with a range of 0.25 to 83 years. All subjects 
had clinical findings consistent with severe envenomation. No adverse reactions 
(hypersensitivity reactions) to AV occurred.  
Median (IQR) total charges was $28,060 ($18,805 - $33,742). Linear regression analysis revealed 
that total number of vials administered, and length of stay were the strongest predictor of total 
charges (adjusted R2 of 0.75). Charges of care increased by $7901.59 per vial of AV and by 
$415.48 for each hour of LOS, both with p < 0.001. 
Cost data was available for 54.8% (N=289) of the study population. Median (IQR) cost was 
$8065 ($5607-$10,086). Linear regression identified age (p<0.001), total number of vials 
(p<0.001), and LOS (p< 0.45) as statistically significant predictors of cost (adjusted R2 of 0.73). 
Median (IQR) fraction of reimbursement was 35.7% (10.9-48.0%) 
Each additional vial of antivenom administered increased total cost by $2540 (p <0.01), and 
each additional hour of length of stay increased total cost by $33 per hour (p=0.045). 
Method of initial antivenom administration did not affect cost, however the total number of 
vials did. And a relatively significant correlation between cost and charges was found (R2=0.78)  
Median (IQR) LOS is 4.0 (3.0-5.0) hours. Linear regression analysis found that total number of 
vials of AV and age were predictors of length of stay but method of AV administration was not.  
The majority of patients were discharged from the emergency department, only 5.1% (27/527) 
were admitted.  Logistic regression was performed to evaluate variables predictive of admission.  
Age > 16 years, hypoxia, fever, and treatment with benzodiazepines were all statistically 
significant predictors of admission, see figure 2.  
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Figure 2. Predictors of Admission in treatment of Severe Envenomation 
Variable Odds Ratio P value 
Age > 16 years* 7.91 <0.001 
Hypoxia 7.36 <0.001 
Fever 7.20 0.002 
Treatment with 
Benzodiazepines 2.85 0.039 
*After inspecting an ROC curve, a cut-off of 16 years of age provided the best balance of 
sensitivity and specificity and was used as the age cut-off in performing logistic regression.  
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The total number of vials are summarized in Table 1, with a minimum of 1 (18.2%) to a 
maximum of 7 (0.4%) with most receiving 3 vials (46.7%). Method of administration is 
summarized in Table 2. Most patients received 3 vials of antivenom initially (52.6%) as 
compared to 1 vial (43.6%) and with only few receiving 2 vials (3.8%) as the initial dose.  
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Table 1. Total Number of Vials Received for Severe Envenomation 
 
Number of Vials Percent (%) 
1 18.2 
2 16.5 
3 46.7 
4 14.2 
5 3.8 
6 0.2 
7 0.4 
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Table 2. Method of Administration: Initial number of vials administered 
Initial Administration ( # of Vials) Percent (%) 
1 43.6 
2 3.8 
3 52.6 
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Chi square test found the most common signs in patients receiving three vials initially were 
those consistent with respiratory or bulbar involvement including hypoxia (65.4%, p=0.003), 
dyspnea (61.1%, p=0.046), and dysphagia/dysarthria (59.4%, p=0.043) See Table 3.   
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Table 3: Factors Strongly Associated with Initial dose of Three Vials 
Clinical Component Percent Population Fraction 
Significance 
(p<0.05) 
Intubation 100.0 5/5 0.039 
Hypoxia 65.4 34/52 0.003 
Dyspnea 61.1 69/113 0.046 
Dysarthria/Dysphagia 59.4 101/170 0.043 
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Table 4 summarizes the clinical manifestations of severe scorpion envenomation in this 
population. There were no deaths and despite hypoxia and respiratory distress occurring in 10% 
and 17.5% of patients respectively, only five were intubated.  Adjunctive treatments utilized in 
this population of patients with severe scorpion envenomation are summarized in Table 5.   
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Table 4: Clinical Signs and Symptoms of Severe Scorpion Envenomation 
Clinical Manifestation Percent 
Abnormal Eye Movement 94.7 
Pain 94.5 
Peripheral Motor Activity 85.4 
Tachycardia 73.7 
Hypertension 71.4 
Hypersalivation 68.9 
Tachypnea 63.4 
Visual Changes 56.0 
Difficulty swallowing/speaking 32.3 
Emesis 30.2 
Pareasthesias* 28.1 
Dyspnea 21.4 
Ataxia 20.7 
Respiratory Distress 17.5 
Hypoxia 10.0 
Diaphoresis 8.2 
Fever 5.5 
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Table 5: Adjuncts Utilized in Addition to Treatment with AV 
Adjunctive Therapy Percent 
Opiates 54.3 
Benzodiazepines 41.2 
Intravenous Fluids 38.2 
Diphenhydramine 17.7 
Atropine 4.6 
Intubation 0.9 
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DISCUSSION 
Centruroides F(ab’)2 antivenom (AV)  is an effective treatment for severe scorpion but as the lay 
press reported and this study confirmed patient incur high charges when receiving this therapy. 
The negative economic impact may be a contributing factor in some clinicians deviating from 
the recommended dosing of an initial dose of 3 vials. A significant portion of this study’s 
population (43.6%) received an initial dose of 1 vial based on their clinical presentation. The 
cumulative dose to reach resolution of symptoms was greater than 3 vials in 56.5% of this 
study’s cases. As illustrated by the results above, the main correlation of increasing total 
charges was antivenom use. There were no other significant predictors of increased total 
charges when analyzed via regression analysis.  
Although the original intent of this study was to compare patient charges to hospital costs; 
however accurate data regarding costs could not be obtained. 45.1% of the reported costs were 
<$2500 which was inaccurate given patients received a minimum of one vial of AV which would 
have resulted in higher costs. The source of the inaccurate cost data could not be identified nor 
rectified we attempted to account for this by statistically analyzing only data with total costs 
greater than $2500 so as to improve the precision and reduce the inaccuracy of flawed cost data 
for 237 cases. Although we recognize this is a limitation of the study the authors felt it was 
important to include as it underscores the difficulty both physicians and patients face by the 
lack of transparency in healthcare economics with little ability to be properly informed about 
the patient charge and the cost of care.  
This retrospective review aimed to quantitate billed charges associated with antivenom use to 
better understand its impact on patient outcomes and healthcare economics. Based on our data 
adjusted to exclude inaccurate cost (less than $2500) the median total charges associated with 
antivenin treatment of a severe bark scorpion envenomation were $28,060 which is significantly 
lower than the reports in the media of upwards of $80,000. This is likely secondary to variances 
not in in antivenin method of administration, but a manifestation of out- of- network healthcare 
coverage in as the woman in the media reports was treated at an out of network facility, 
increasing her total charges significantly. Additionally, in comparing media reports to the cost 
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and charge data, there is limited access to what, if any, adjunctive therapies were administered 
and their effect on the final charges. However, as the average American has approximately 
$17,000 in savings a healthcare bill of tens of thousands of dollars can completely derail an 
individual or family, and the results of this study can serve to facilitate conversation between 
patients and their providers on guiding treatment while being mindful of cost and healthcare 
resources.  
Although dosing guidelines suggest a 3 vial protocol, it should be noted that in 43.5% of cases, 
the cumulative dose needed to resolve symptoms was limited to 1-2 vials. This amounts to cost 
savings of $2540 per vial not needed and the cost of monitoring for per additional hour of $33 is 
worthy of consideration in management of severe scorpion envenomations without signs of 
airway compromise or severe neurologic symptoms. As the current climate of the United States 
healthcare system is one of many layers and basic estimated costs are frequently shrouded in 
medicolegal jargon the data of this study provides a basis for which to explore observation vs 
additional pharmacologic intervention in appropriate cases. 
 By increasing these conversations, it is possible that the use of adjunctive therapies would 
increase overall and could be explored in further studies. Currently, it is not uncommon to 
require pharmacologic therapy for pain, agitation & anxiety control as the scorpion venom is a 
powerful neurotoxin and time to resolution of symptoms even with antivenom administration 
can take up to several hours to reach its peak efficacy in binding the venom and reducing its 
clinical effects.  Additionally, the preparation of the antivenom can often present as a time-
consuming process as it is kept in a lyophilized powder form that requires rehydration and 
dilution with sterile saline prior to its infusion over a 10 minute period of time. Adjunctive 
therapies such as opiates and benzodiazepines have variable efficacy in managing symptoms 
associated with severe envenomations, likely based on individual tolerance and pain thresholds. 
It is notable that when analyzing our data if a patient was hypoxic and received treatment with 
benzodiazepines they were 21 times more likely to be admitted.  
In the southwestern United States, envenomation by the bark scorpion, Centruroides 
sculpturatus, can result in a spectrum of illness ranging from mild to fatal.  Its venom blocks 
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inactivation of neuronal sodium channels resulting in increased influx of sodium. This produces 
increased duration and amplitude of the neuronal action potential and enhanced release of 
neurotransmitters such as acetylcholine and norepinephrine. Clinically this manifests as 
cholinergic and adrenergic stimulation, producing a myriad of signs and symptoms such as 
skeletal motor and parasympathetic stimulation. Although the pathophysiology of bark scorpion 
envenomation is well understood, the accumulation of charges related to these envenomations 
is more opaque. Although costly, antivenom treatment has been shown to reduce patient’s 
length of stay after hospital presentation from 12 hours to only four hours. (Boyer 2009).In a 
report published by the VA Pharmacy Benefits Management Services, the average cost of 
treatment associated with 3 vials post envenomation was approximately $8000 however there 
was no data released surrounding charges and total costs as it related to therapeutic 
treatment.(National 2012) 
The results of this study indicate that median charges for treatment of scorpion envenomation 
with AV are approximately thirty thousand dollars, with the only predictor of increased total 
charges being age, total number of vials and overall length of stay. Interestingly, the presence of 
more severe signs of envenomation such as hypoxia, intubation or respiratory distress were not 
predictors of increased total charges. Of the 527 cases reviewed, there were no documented 
adverse effects or anaphylactic reactions in the administration of antivenom. The dichotomous 
style of antivenom administration predominating in three-vials initially and one vial initially was 
an unexpected finding. However, these results may be influenced by a discontinued institutional 
policy that in the past required antivenom to be dosed one vial at a time with re-evaluation of 
the patient, in an attempt to preserve resources and control costs.   Another possible reason for 
this method of antivenom administration is that healthcare facilities near the Biotechnology 
Institute in Mexico, where the antivenom is created, tend to use an administration protocol that 
favors giving one vial initially as well.  
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LIMITATIONS 
There were several limitations to this study. The first limitation was the retrospective nature of 
the study, which made it difficult to ascertain various details such as timing of symptoms, as 
well as the accuracy of the provider’s evaluation of the severity of envenomation. Additionally, 
although access was obtained to the financial data providing patient charges and costs it was 
found after detailed review that despite accurate charge data, a subset of patients included in 
the study had incredibly low total costs, under $2500. This could not be explained or corrected 
when explored by the investigators, and additional information sought by the financial 
department of the hospital system. Despite this significant limitation, we the authors felt that 
the 289 cases for which there was accurate cost and charge data available the results merited 
exploration. Therefore, data collected was analyzed conditionally and costs amounting to less 
than $2500 were excluded from the dataset as to prevent skewing data with inaccurate outliers.  
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FUTURE DIRECTIONS 
The current climate of the US healthcare system is one that continues to bear difficulties for 
consumers and providers alike in the often-elusive details and unclear costs of care. The 
importance of recognition, triage and treatment of severe scorpion envenomation in 
combination with its recent media coverage provided an opportunity to bring to light the 
realities of cost of care in the US healthcare system, and future studies investigating 
overarching costs of care and assessment of financial literacy are warranted to increase 
transparency between insurance coverage, patients and their healthcare providers. 
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CONCLUSION 
Despite its high cost to patients and hospital systems, Centruroides F(ab’)2 antivenom remains a 
safe and effective therapy for severe scorpion envenomation in both the adult and pediatric 
population. This study demonstrates that healthcare providers are aware of the cost of therapy 
and often make attempts to minimize cost to their patients and healthcare system.  Despite 
these efforts, in the majority of cases the recommended dosing regimen of three vials is 
required to achieve symptom resolution, in addition to improving total length of stay.  
Total number of AV vials administered was the strongest predictor of total billed charges. 
Despite apparent attempts by healthcare providers to minimize vials of AV given the majority of 
patients required 3 or more vials of AV.    
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APPENDIX 
# 1 – DATA ABSTRACTION SHEET 
ADULT SCORPION STINGS:  DATA ABSTRACTION SHEET 
(record findings at peak symptoms, whether upon presentation or if after obs prd) 
        
SUBJECT #   Age      
     Time of sting   
Date   Sex    Time sx onset   
     Time to HCF   
        
Signs:  eyes yes no Vitals: HR   
  motor act. yes no  BP   
  hypersal yes no  RR   
  diaphoresis yes no  
Max 
Temp   
  resp distress yes no  O2sat   
  vomiting yes no  (RA/O2)   
           if yes: pre-hosp ED    
  ataxia yes no    
        
Antivenom 
Given yes no  available / not available  
        
        
Patient 
complaints: pain  diff ambulating   
  paresthesias  other (i.e swelling, rash, wheezing) 
  diff swallowing     
  visual sxs      
  dyspnea      
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Treatment prior to hospital 
arrival: DPH     
   atropine     
   APAP 
NSAI
D    
   intubation     
   benzo/dose:       
   opiate/dose:       
   IVF     
   other:     
        
Treatment in hospital:(circle) IVF     
   O2 via:      
   atropine     
   intubation     
   benzo:       
   opiate:       
   other:     
        
 CPK? no yes: peak   Rhabdo? yes  
     max Cr:   
time since 
sting: 
 
 
EKG? no yes  results   
 
 
CXR? no yes   aspiration? no yes 
        
 Length of stay:   hours    
        
Comments/Complications:           
        
Other relevant information: _________________________________________    
 
